palmitoylethanolamide.com.au
HomeResearchAyat 2022

Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules

Ayat Zagzoog, Ashley Cabecinha, Hanan Abramovici, Robert B Laprairie. Front Pharmacol. 2022 Aug 26:13:956030.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Chinese hamster ovary cells expressing human CB1R; male mice for selected compounds
Dose used in the study
Ten phytomolecules including palmitoylethanolamide, with or without delta-9-THC; concentrations and doses not stated in the abstract
Duration
Not stated in the abstract
What was measured
CB1R binding, inhibition of forskolin-stimulated cAMP and beta-arrestin2 recruitment in cells; catalepsy, hypothermia and anti-nociception in mice for selected compounds

What the authors reported

The cannabinoids tested showed partial agonist activity at CB1R, and the phytomolecules modulated delta-9-THC-dependent binding and signalling in vitro and in vivo. The abstract does not report PEA-specific results.

Limits of this study

A cell and mouse study; it cannot show effect in people. PEA-specific findings are not given in the abstract. The authors declare no commercial or financial conflicts.

Source

PubMed 36091813 · doi:10.3389/fphar.2022.956030

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.